Five Undervalued Stocks for 2026: Experts See 20-40% Upside Potential
Top brokerages have identified five stocks including Aurobindo Pharma and Kalpataru Power Solutions as compelling long-term buys with potential returns of 20-40% in 2026.
Brokerage Recommendation
Multiple Brokerages
Five Undervalued Stocks for 2026: Experts See 20-40% Upside Potential
As investors plan their 2026 portfolios, several top brokerage firms have identified promising opportunities in the Indian stock market. A curated selection of recommendations highlights five stocks expected to deliver meaningful returns over the medium to long term.
Aurobindo Pharma Emerges as Key Pick
Among the standout recommendations, Aurobindo Pharma [AUROPHARMA] features prominently in brokerage calls. The pharmaceutical company is viewed as an attractive entry point for long-term investors, with analysts projecting potential gains in the 20-40% range throughout 2026.
Aurobindo's strong fundamentals in the global pharmaceutical space, coupled with its expanding product portfolio and improving operational efficiencies, form the basis for bullish sentiment. The company's competitive positioning in regulated markets continues to support analyst optimism.
Kalpataru Power Solutions in Focus
Another notable recommendation is Kalpataru Power Solutions [KALPATURPOW], a leader in the power transmission and distribution sector. Infrastructure-focused stocks have gained traction as the government accelerates capital expenditure on grid modernization and renewable energy integration.
Analysts believe Kalpataru is well-positioned to benefit from India's ambitious energy infrastructure expansion plans, making it an attractive long-term accumulation opportunity.
Broader Market Context
The brokerage consensus reflects optimism about select mid and large-cap stocks that combine reasonable valuations with strong growth catalysts. Rather than broad market enthusiasm, the recommendations focus on companies with structural tailwinds and robust business fundamentals.
Investors considering these stocks should evaluate their own risk tolerance, investment horizon, and portfolio allocation before committing capital. While 20-40% upside projections appear attractive, actual returns depend on market conditions, company execution, and macroeconomic factors.
Key Takeaway
The 2026 outlook from leading brokerages emphasizes quality over quantity, favoring companies with defensible competitive advantages and clear growth pathways. Both Aurobindo Pharma and Kalpataru Power Solutions exemplify this selective approach to long-term wealth creation.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Stock market investments are subject to market risks. Please consult your financial advisor before making any investment decisions. StockTips.in is not a SEBI-registered investment advisor.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Stock market investments are subject to market risks. Please consult your financial advisor before making any investment decisions. StockTips.in is not a SEBI-registered investment advisor.